CorNeat Vision develops new nanotech solution that could one day help restore sight to millions who have gone blind due to diseases of the cornea.
An early-stage Israeli ophthalmic medical devices startup has developed a revolutionary artificial cornea implant that holds out hope to millions of blind and visually impaired people suffering from diseases of the cornea.
The nanotech-based solution by CorNeat Vision of Ra’anana is a synthetic cornea that uses advanced cell technology to integrate artificial optics within ocular tissue.
After successful initial tests on animals, the company plans to move to human implantations in Israel in the middle of next year, and also to begin a larger clinical trial of 20 to 60 patients in the United States.
According to the World Health Organization, diseases of the cornea are the second leading cause of blindness worldwide, second only to cataracts. As many as 30 million people are affected, with around two million new cases each year.
“Though [corneal diseases are] a profound cause of distress and disability, existing solutions such as corneal transplantation are carried out only about 200,000 times a year worldwide,” said 47-year-old CorNeat Vision CEO and VP R&D Almog Aley-Raz.
“There exists an urgent need for an efficient, long-lasting and affordable solution to corneal pathology, injury and blindness, which would alleviate the suffering and disability of millions of people.”
CorNeat’s implant, the CorNeat KPro, which is to be unveiled to select members of the ophthalmic community at the XXXV European Society of Cataract and Refractive Surgeons Congress (ESCRS) in Lisbon, Portugal this week, has just been cleared by the European Patent Office.
CorNeat KPro uses advanced cell technology to integrate artificial optics within resident ocular tissue. The implant is produced using nanoscale chemical engineering that stimulates cellular growth.
“Unlike previous devices, which attempt to integrate optics into the native cornea, CorNeat’s implant leverages a virtual space under the conjunctiva that is rich with fibroblast cells, heals quickly and provides robust long-term integration,” said Aley-Raz.
The surgical procedure takes just 30 minutes, and the company believes it can provide an efficient and scalable remedy for millions.
To read more about this innovation from Israel21c please click here.